During the long downturn in R&D productivity, a handful of bio-pharmaceutical companies have consistently bucked the trend. How did they manage it? After all, they have experienced the same industry pressures as their peers - pressures such as lengthier R&D cycle times, higher costs of failure, and sharper regulatory scrutiny.